DPP4 and hepatocellular carcinoma: We provide proof-of-concept evidence that inhibiting the DPP4 enzyme family using ARI-4175 could reduce the number of macroscopic liver nodules, increase CD8+ T cell abundance and increase inflammasome activation during an early stage of development of HCC.